AMDL Launches New JPGreen Business Strategy
November 20 2007 - 6:13PM
PR Newswire (US)
TUSTIN, Calif., Nov. 20 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), with operations in Shenzhen, Jiangxi and Jilin, China,
through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI),
an international biopharma company that engages in the development,
manufacture and marketing of proprietary pharmaceutical and
diagnostic products, announced today that it has launched
significant new expansion plans to increase annualized sales in
FY2008, through the introduction of multiple new products and
distribution strategies. In concert with the expansion of JPI's new
Goodnak product, JPI expects to significantly expand its new
JPGreen Health & Beauty Centers that are anticipated to provide
a wide variety of anti-aging, beauty, cosmetic and spa related
treatments and products for both women and men. There are currently
five existing Jade Healthy Supermarkets store locations, which were
previously announced, that are in the process of being converted
into the new JPGreen retail store design. Any future acquired
stores will also be re-decorated in JPGreen style, and will
highlight JPGreen and JPI products. These JPGreen locations,
typically 300-900 square feet in size, are being developed through
in-house store openings and through the acquisition of existing
beauty and spa businesses. The typical JPGreen store location is
anticipated to generate, on average, approximately $170,000 in
annual sales with an average net profit margin of at least 30
percent. JPI has initially signed over 50 letters of intent with
various existing beauty and spa businesses that have indicated
their interest in being acquired and converted to JPGreen stores.
JPI currently anticipates acquiring and converting up to 200
locations during late FY2007 and FY2008. Frank Zheng, managing
director of JPI, said this new expansion of the JPGreen store model
has been well thought out and the company has the management talent
pool and operational resources to meet this challenging expansion
goal. Gary Dreher, CEO of AMDL said, "We expect to be in a position
to provide the capital resources JPI will need in the coming months
to allow them to execute their plans in a timely manner. We look
forward to highly profitable China based operations in FY2008.
We'll continue to update the market as JPI achieves various
milestones related to this expansion strategy." About JPI: Jade
Pharmaceutical through its subsidiaries JJB & YYB has access to
the fastest growing pharmaceutical and consumer market in the
world: China. AMDL, through its subsidiary, Jade currently
manufactures large volume injectable fluids, tablets and other
related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. About AMDL: More information about AMDL
and its products can be obtained at http://www.amdl.com/.
Forward-Looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: AMDL Investor Relations, Paul Knopick, +1-949-707-5365,
VoiceMail, +1-714-505-4460 Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024